

# ADDEX THERAPEUTICS LTD. SPON. ADR

ISIN: US00654J2069 WKN: 00654J206 Asset Class: Stock

## Company



2024/10/18 22:30:00

Price

**10.44**

USD

Difference

**-1.51% (-0.16)**



## Contact Details

ADDEX THERAPEUTICS LTD.

Tel: +41-22-884-15-55

--

Fax: +41-22-884-15-56

9, Chemin des Mines,  
Plan-les-Ouates

Web:  
<http://www.addextherapeutics.com>

1202 Genf

E-mail:  
[info@addextherapeutics.com](mailto:info@addextherapeutics.com)

## Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023      |                        | 2022      |                        | 2021       |                        |
|--------------------------------|-----------|------------------------|-----------|------------------------|------------|------------------------|
|                                | Assets    | Liabilities and equity | Assets    | Liabilities and equity | Assets     | Liabilities and equity |
| Current assets                 | 4,233,000 |                        | 7,825,000 |                        | 21,924,000 |                        |
| Common stock capital           |           | 1,843,000              |           | 1,153,000              |            | 49,272,000             |
| Fixed assets                   | 407,000   |                        | 453,000   |                        | 600,000    |                        |
| Equity capital of a company    |           | 1,144,000              |           | 4,909,000              |            | 16,913,000             |
| Cash and cash equivalents      | 3,865,000 |                        | 6,957,000 |                        | 20,484,000 |                        |
| Accrued liabilities            |           | 443,000                |           | 0                      |            | 1,281,000              |
| Other assets                   | -         |                        | -         |                        | -          |                        |
| Current liabilities            |           | 2,893,000              |           | 3,282,000              |            | 4,134,000              |
| Prepayments and accrued income | -         |                        | -         |                        | -          |                        |
| Non-current liabilities        |           | 603,000                |           | 87,000                 |            | 1,475,000              |
| Different income               |           | -                      |           | -                      |            | -                      |
| Other liabilities              |           | 89,000                 |           | 0                      |            | 0                      |
| Total assets                   | 4,641,000 | 4,641,000              | 8,278,000 | 8,278,000              | 22,524,000 | 22,524,000             |

## Balance notes

|                     | 2023    | 2022   | 2021   |
|---------------------|---------|--------|--------|
| Accounting standard | IFRS    | IFRS   | IFRS   |
| Employees           | 23      | 24     | 28     |
| Equity ratio        | 24.66%  | 59.30% | 75.09% |
| Debt-equity ratio   | 305.47% | 68.62% | 33.17% |

## Others

|                  | 2023  | 2022  | 2021  |
|------------------|-------|-------|-------|
| Tax Expense Rate | 0.00% | 0.00% | 0.00% |

# ADDEX THERAPEUTICS LTD. SPON. ADR

ISIN: US00654J2069 WKN: 00654J206 Asset Class: Stock

## Income statement

|   | 2023        | 2022        | 2021        |
|---|-------------|-------------|-------------|
| Turnover  | 1,617,000   | 1,444,000   | 2,934,000   |
| Net income  | -10,556,000 | -20,804,000 | -15,351,000 |
| EBIT  | -11,277,953 | -22,116,858 | -16,274,584 |
| Operating income before taxes                                 | -10,556,000 | -20,804,000 | -15,351,000 |
| Cash Flow   | -7,950,000  | -16,456,000 | -14,762,000 |
| Net interest income   | 42,000      | -19,000     | -57,000     |
| Research and development expenses                             | 6,759,000   | 14,447,000  | 12,567,000  |
| Income taxes  | 0           | 0           | 0           |
| Result from investments in subsidiaries, associates and other | 0           | 0           | 0           |
| Revenues per employee   | 74,820      | 64,066      | 111,540     |

## Board of Directors

|                |                                      |
|----------------|--------------------------------------|
| Isaac Manke    | Member of the administrative board   |
| Raymond Hill   | Member of the administrative board   |
| Roger Mills    | Member of the administrative board   |
| Jake Nunn      | Member of the administrative board   |
| Vincent Lawton | Chairman of the administrative board |

## Members of Management Board

|                    |                               |
|--------------------|-------------------------------|
| Timothy Dyer       | Chairman of Managing Board    |
| Lénaïc Teyssédou   | Member of Executive Committee |
| Mikhail Kalinichev | Member of Executive Committee |
| Roger Mills        | Member of Executive Committee |